On November 10, 2025, Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, announced that it has raised approximately $100 million in an oversubscribed financing round. Wilson Sonsini Goodrich & Rosati advised Iambic on the transaction.

The financing received support from new and existing investors, including Abingworth, Alexandria Venture Investments, Alumni Ventures, ARK, Ascenta, Catalio, Everbright Biofund, Freeflow Ventures, Illumina Ventures, Mubadala, Pegasus Tech Ventures, Qatar Investment Authority, Regeneron Ventures, Sequoia, Tao Capital Partners, Terra Magnum Capital Partners, Wilson Sonsini, and others. 

The team that advised Iambic on the transaction includes:

Corporate
Zach Myers
Nathan Robinson
Aletha Tarn
Bridget Balisy

Intellectual Property
Matt Bresnahan
Grant Margulieux

Technology Transactions
Ian Edvalson

Regulatory
Josh Gruenspecht

For more information, please see Iambic's news release.